ArticleJCI insight2022
Group IIA secreted phospholipase A2 controls skin carcinogenesis and psoriasis by shaping the gut microbiota.
Article in JCI insight, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Ginsenoside Rk3 modulates glutamine metabolism and inhibits Th17 cell differentiation via gut microbiota regulation to ameliorate psoriasis.Journal of natural medicines · 2026Article
- The Phospholipase AJournal of lipid and atherosclerosis · 2026Review
- Secreted phospholipase PLA2G5 acts as a hemolytic factor in sepsis.The Journal of clinical investigation · 2026Article
- Article
- Secretory phospholipase ACommunications biology · 2025Article
- Secreted phospholipase A2 regulates intercellular communications by coordinating extracellular phospholipid metabolism.International immunology · 2025Review
- Secreted phospholipase A2 regulates intercellular communications by coordinating extracellular phospholipid metabolism.International immunology · 2025Review
- sPLA2-IIA modifies progranulin deficiency phenotypes in mouse models.Molecular neurodegeneration · 2025Article
- sPLA2-IIA modifies progranulin deficiency phenotypes in mouse models.Molecular neurodegeneration · 2025Article
- Ursolic Acid as a Protective Agent against UVB-Induced Metabolic and Epigenetic Alterations in Human Skin Keratinocytes: An Omics-Based Study.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- Secreted Phospholipases A2: Drivers of Inflammation and Cancer.International journal of molecular sciences · 2024Review
- Single-cell transcriptomics analysis of bullous pemphigoid unveils immune-stromal crosstalk in type 2 inflammatory disease.Nature communications · 2024Article
- Secreted phospholipase PLA2G2E contributes to regulation of T cell immune response against influenza virus infection.Journal of virology · 2024Article
- Secreted phospholipase PLA2G2E contributes to regulation of T cell immune response against influenza virus infection.Journal of virology · 2024Article
- Modulation of Airway Expression of the Host Bactericidal Enzyme, sPLA2-IIA, by Bacterial Toxins.Toxins · 2023Review
- The Roles of sPLABiomolecules · 2023Review
- Metabolic influences on T cell in psoriasis: a literature review.Frontiers in immunology · 2023Review
- Advances in psoriasis and gut microorganisms with co-metabolites.Frontiers in microbiology · 2023Review
- Old but New: Group IIA Phospholipase AMetabolites · 2022Review
- The interaction of secreted phospholipase A2-IIA with the microbiota alters its lipidome and promotes inflammation.JCI insight · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Besides promoting inflammation by mobilizing lipid mediators, group IIA secreted phospholipase A2 (sPLA2-IIA) prevents bacterial infection by degrading bacterial membranes. Here, we show that, despite the restricted intestinal expression of sPLA2-IIA in BALB/c mice, its genetic deletion leads to amelioration of cancer and exacerbation of psoriasis in distal skin. Intestinal expression of sPLA2-IIA is reduced after treatment with antibiotics or under germ-free conditions, suggesting its upregulation by gut microbiota. Metagenome, transcriptome, and metabolome analyses have revealed that sPLA2-IIA deficiency alters the gut microbiota, accompanied by notable changes in the intestinal expression of genes related to immunity and metabolism, as well as in the levels of various blood metabolites and fecal bacterial lipids, suggesting that sPLA2-IIA contributes to shaping of the gut microbiota. The skin phenotypes in Pla2g2a-/- mice are lost (a) when they are cohoused with littermate WT mice, resulting in the mixing of the microbiota between the genotypes, or (b) when they are housed in a more stringent pathogen-free facility, where Pla2g2a expression in WT mice is low and the gut microbial compositions in both genotypes are nearly identical. Thus, our results highlight a potentially new aspect of sPLA2-IIA as a modulator of gut microbiota, perturbation of which affects distal skin responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.